Media Coverage

Obesity, complexity, and the lab: What 2025 taught us, and what comes next

Hvivo appoints veteran pharma executive to board

Unlocking the future of obesity treatment

MSD to acquire Cidara after positive phase 2b trial results

Cidara and hVIVO report positive results in flu prevention study

A cash-rich stock with the foundations for growth

SMALL CAP IDEA: 'Flu Camp' rapid drug trial firm slashes big pharma costs

This lowly rated research stock is a real bargain

MARKET REPORT: Bad news for WPP as advertising giant warns of a dire year ahead

Hvivo acquires clinical storage specialist

Cathal Friel-chaired Hvivo acquires bio storage group Cryostore in €3.9 million deal

Hvivo secures £2m deal with a new biopharmaceutical client

HVIVO: Research firm announces final stage of study on cold-like virus human metapneumovirus

Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO

hVIVO acquires Germany’s CRS for ‘significant European foothold’

Inhalon launches human challenge trial for RSV treatment

hVIVO plans challenge trial for RSV antiviral candidate

BRIEF—hVIVO acquires two German clinical research units

Hvivo reports record revenues and the acquisition of a German research firm

hVivo expands with acquisition of German clinical trial units

Clinical trials group Hvivo expands into Germany with €10m acquisition

Hvivo’s shares rise 8.5% as it signs world’s first ‘Phase 3’ human trial for whooping cough

Hvivo to tackle whooping cough with its biggest ever human trial

Hvivo secures £2.7m contract, marking largest deal to date

Is HMPV in the UK and how worried should we be? Experts weigh in

Is this the start of a new pandemic? As hMPV cases rise, everything you need to know about the 'mystery' illness

Urgent HMPV warning as virus cases double in Britain in under a month

Could the mystery China hMPV virus outbreak trigger a pandemic? Experts give verdicts

HPMV cases DOUBLE in Britain with experts urging China to disclose vital information on outbreak

Should Britain be worried about the virus spreading in China?

UK experts urge China to reveal crucial details of HPMV outbreak - as cases DOUBLE in Britain

Patients who've been struck down by virus ravaging China describe horrific symptoms: 'Worst I've ever felt'

HMPV outbreak: How it's SOARING in the 'super-spreader' under 5 year-olds...who are most at risk of serious illness

HMPV outbreak: UK experts call for more information on virus in China as London scientists play down risk

CEO update - 16 December 2024 | BIA

Hvivo signs €14 million contract with ‘global pharma client’ and confirms guidance

hVIVO shares rise on contract win and reaffirmed revenue guidance

Would you volunteer to get yourself infected with flu in Canary Wharf?

Eight AIM shares ripe for a rally as Budget concerns subside

How to revive the UK's small-cap sector

hVIVO is in pole position to capitalise on increasing interest in human challenge trials

hVIVO – Institutional Holdings Building Up After This Week’s Strong First Half Report

hVIVO hails ‘record’ half-year revenue, as profit soars 70% higher

hVIVO has foundations for strong growth

Strong first half for Hvivo puts company on track to meet full year guidance

Clinical trial specialist hVivo's H1 revenues jump by 30%

Irish-founded Hvivo posts record revenue with 30 per cent jump in H1

Earnings rise 68pc at pharmaceutical services firm Hvivo

hVIVO earnings up by 67.6% in first half

hVIVO – Foundations Laid For Strong Performance In The Months And Years Ahead, Institutions Building Up Stakes Ahead Of Interims

Inside Canary Wharf’s infectious disease testing facility

‘Fail fast. Succeed fast.’ Inside Hvivo’s new Canary Wharf human trials facility

HVIVO Reports 30% Increase In H1 Revenue Following Canary Wharf Move

‘Search mode’: Human challenge trial company looks to buy small CROs

hVIVO reports 31% revenue jump; relocation to improve efficiencies

MARKET REPORT: Rout wipes £260 billion off trio of US tech titans

Research firm Hvivo records 31pc jump in revenues in first half

Hvivo reports 30% revenue increase following record number of volunteer inoculations

Hvivo revenue reaches record in fist half of 2024

hVIVO gathers momentum as revenue jumps 30%

hVIVO on the upgrade again

Is it worth £7000 to be infected with a disease and go into lockdown?

Expert View: Sage, Craneware, Quilter, Sainsbury’s, Hvivo

Hvivo signs largest field study contract to date

Research firm hVivo to begin study into Omicron vaccine

Hvivo seals €2.9m contract for Covid-19 characterisation study

Hvivo has strong upside potential – even using conservative targets

Big Pharma Warms To HVIVO Human Challenge Clinical Trials

Increased demand boosts revenues at hVIVO as it eyes acquisitions

Earnings rise 44pc at pharmaceutical services firm hVIVO

hVIVO reports higher profits and revenues for 2023

hVIVO on track to hit target as it records revenue high in 2023

The hunt for good-value UK stocks

Private Investor's Diary: Four new companies for my portfolio

Business is booming at hVIVO

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

hVIVO's 2023 revenues rise by 15.5%

MARKET REPORT: Profit warning hammers shares in Speedy Hire

Investors hope Auction Technology Group will go under the hammer

hVIVO shares surge as revenue jumps, regular dividends planned in 2024

Life sciences firm hVIVO has record year as Canary Wharf site set for completion

Cathal Friel’s Hvivo plans cash return for investors as sales are forecast to hit £100m by 2028

Hvivo raises revenue targets as business continues to grow

Top marks again for high-flying M&S

MARKET REPORT: Shares in Marks & Spencer make a sparkling start to 2024

Hvivo signs €7.3m contract to test cold virus treatment

Hvivo signs €7.3m contract to test common cold treatment

HVIVO Signs €7.3m Testing Contract With Biotechnology Client

Irish-listed Hvivo signs €7.3m contract with biotechnology firm